Multicenter Trial of the Edmonton Protocol to Begin in Fall 2000
Beginning in the fall of 2000, ten centers around the world will attempt to replicate the success of the Edmonton Protocol for islet cell transplants, President Clinton announced on July 13, 2000. Approximately 40 patients will receive islet cell transplants over the next 18 months. Children are not included in these trials.
Participating CentersNorth America Centers
- University of Alberta Islet Transplantation Program, Edmonton, Alberta, Canada
- Diabetes Research Institute, University of Miami, Miami, Florida
- Diabetes Institute for Immunology and Transplantation, University of Minnesota, Minneapolis, Minnesota
- Juvenile Diabetes Foundation Center for Islet Transplantation, Harvard Medical School, Boston, Massachusetts
- Diabetes Research Training Center, Washington University, St. Louis, Missouri
- Pacific Northwest Research Institute, Seattle, Washington
- Organ/Tissue Transplant Research Center, National Institutes of Health, Washington, D.C.
Patient Selection CriteriaMen and women between the ages of 18 to 65 who have had type 1 diabetes at least five years and who:
- cannot control their blood sugar even with intensive insulin therapy
- do not adequately sense the onset of hypoglycemia (low blood sugar)
- have had a least one hypoglycemic reaction in the last 1.6 years that cannot be otherwise explained and required medical attention
- have secondary complications of diabetes, such as progressive vision, kidney, nerve or vascular problems despite efforts to optimize control of blood sugar
Patients with severe cardiac disease, active or recent history of substance abuse (including smoking), excessive insulin resistance, or an active infection (including hepatitis B or C, HIV, or TB) are not eligible.
Patient Information HotlinesMore information for patients wishing to participate is available on the Immune Tolerance Network web site or from the ITN Patient Referral Hotline at (773) 834-5341 in the United States. Canadian residents may phone (780) 407-1501. Referral forms are to be completed, signed by the patient's physician and returned by January 1, 2001. Patients who appear to meet all the criteria will be contacted for further consultation prior to a final evaluation.
For More Information
- President Clinton Announces Major New Investment in Diabetes Research, Treatment, and Prevention.
- NIH Press Release on the New Clinical Trials
- Immune Tolerance Network Summary of the New Trials
- Immune Tolerance Network Press Release
- University of Alberta News about the New Trials
- Harvard University Press Release
- JDF News Release
- Alberta Foundation Reports on Successful Islet Transplants (original story)
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen (original publication in the New England Journal of Medicine)
Posted July 16, 2000
|Return to the Top of This Page|
Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.